Evidence map›Paper›PMID 33557115›Full record

ArticleMolecules (Basel, Switzerland)2021

Combining Different Docking Engines and Consensus Strategies to Design and Validate Optimized Virtual Screening Protocols for the SARS-CoV-2 3CL Protease.

Candida Manelfi, Jonas Gossen, Silvia Gervasoni, Carmine Talarico, Simone Albani, Benjamin Joseph Philipp, Francesco Musiani, Giulio Vistoli, Giulia Rossetti, Andrea Rosario Beccari and 1 more

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Article
  2. Approaching Pharmacological Space: Events and Components.Methods in molecular biology (Clifton, N.J.) · 2025
    Article
  3. Article
  4. Review
  5. A review onExploration of targeted anti-tumor therapy · 2023
    Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Virus structure and structure-based antivirals.Current opinion in virology · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Candida ManelfiDompé Farmaceutici SpA, Via Campo di Pile, 67100 L'Aquila, Italy.ORCID 0000-0002-9175-243X
Jonas GossenComputational Biomedicine, Institute for Neuroscience and Medicine (INM-9) and Institute for Advanced Simulations (IAS-5), Forschungszentrum Jülich, 52425 Jülich, Germany.
Silvia GervasoniDipartimento di Scienze Farmaceutiche, Università degli Studi di Milano, Via Mangiagalli, 25, I-20133 Milano, Italy.ORCID 0000-0002-5731-3396
Carmine TalaricoDompé Farmaceutici SpA, Via Campo di Pile, 67100 L'Aquila, Italy.ORCID 0000-0003-4789-0955
Simone AlbaniComputational Biomedicine, Institute for Neuroscience and Medicine (INM-9) and Institute for Advanced Simulations (IAS-5), Forschungszentrum Jülich, 52425 Jülich, Germany.ORCID 0000-0002-3560-4539
Benjamin Joseph PhilippComputational Biomedicine, Institute for Neuroscience and Medicine (INM-9) and Institute for Advanced Simulations (IAS-5), Forschungszentrum Jülich, 52425 Jülich, Germany.
Francesco MusianiLaboratory of Bioinorganic Chemistry, Department of Pharmacy and Biotechnology, University of Bologna, 40127 Bologna, Italy.ORCID 0000-0003-0200-1712
Giulio VistoliDipartimento di Scienze Farmaceutiche, Università degli Studi di Milano, Via Mangiagalli, 25, I-20133 Milano, Italy.ORCID 0000-0002-3939-5172
Giulia RossettiComputational Biomedicine, Institute for Neuroscience and Medicine (INM-9) and Institute for Advanced Simulations (IAS-5), Forschungszentrum Jülich, 52425 Jülich, Germany.ORCID 0000-0002-2032-4630
Andrea Rosario BeccariDompé Farmaceutici SpA, Via Campo di Pile, 67100 L'Aquila, Italy.ORCID 0000-0001-6830-2695
Alessandro PedrettiDipartimento di Scienze Farmaceutiche, Università degli Studi di Milano, Via Mangiagalli, 25, I-20133 Milano, Italy.ORCID 0000-0001-5916-2029

Funding

Horizon 2020 101003551
6 · The paper itself

Abstract

The 3CL-Protease appears to be a very promising medicinal target to develop anti-SARS-CoV-2 agents. The availability of resolved structures allows structure-based computational approaches to be carried out even though the lack of known inhibitors prevents a proper validation of the performed simulations. The innovative idea of the study is to exploit known inhibitors of SARS-CoV 3CL-Pro as a training set to perform and validate multiple virtual screening campaigns. Docking simulations using four different programs (Fred, Glide, LiGen, and PLANTS) were performed investigating the role of both multiple binding modes (by binding space) and multiple isomers/states (by developing the corresponding isomeric space). The computed docking scores were used to develop consensus models, which allow an in-depth comparison of the resulting performances. On average, the reached performances revealed the different sensitivity to isomeric differences and multiple binding modes between the four docking engines. In detail, Glide and LiGen are the tools that best benefit from isomeric and binding space, respectively, while Fred is the most insensitive program. The obtained results emphasize the fruitful role of combining various docking tools to optimize the predictive performances. Taken together, the performed simulations allowed the rational development of highly performing virtual screening workflows, which could be further optimized by considering different 3CL-Pro structures and, more importantly, by including true SARS-CoV-2 3CL-Pro inhibitors (as learning set) when available.

Indexed as

Antiviral AgentsBinding SitesCoronavirus 3C ProteasesCOVID-19COVID-19 Drug TreatmentDrug DesignDrug Evaluation, PreclinicalDrug RepositioningHumansModels, MolecularMolecular Docking SimulationPeptide HydrolasesProtease InhibitorsProtein ConformationSARS-CoV-23C-like protease, SARS coronavirusAntiviral AgentsCoronavirus 3C ProteasesPeptide HydrolasesProtease Inhibitors3CL-Proantiviralsbinding spaceconsensus modelsdocking simulationsdrug repurposingisomeric spaceSARS-CoV-2virtual screening

Identifiers

PMID33557115
PMCPMC7913849

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.